Built on the most-studied non-invasive vagal pathway.
Lull uses transcutaneous auricular vagus nerve stimulation (taVNS) — a mechanism that's been in independent, peer-reviewed research since 2007. Here's exactly what the research says, what it doesn't, and how our device is built around it.
Key research outcomes
The method Lull is built around — transcutaneous auricular vagus nerve stimulation (taVNS) — has been examined in independent, peer-reviewed and placebo-controlled research. Across that literature, the measurable benefits cluster in three areas:
How It Works
Lull supports healthy brain chemistry and strengthens neuroplasticity
taVNS is associated with increased activity in brainstem centres that regulate norepinephrine — involved in mood, focus and learning (Zheng et al., 2024).
Your brain is an efficiency machine. Through neuroplasticity it prunes away the connections you use least — so whichever circuits you fire most become your "default" setting. When the nervous system is flooded with stress signals day after day, calm becomes the circuit that gets pruned, and the body stays braced for danger.
By gently stimulating the vagus nerve at the ear, Lull nudges the nervous system back toward its parasympathetic "rest and digest" state — the conditions under which mood, focus and recovery are regulated. With consistent short sessions, the aim is to help the body re-learn calm as a default rather than the exception.
Lull helps calm the body's inflammatory response through the vagal pathway
The vagus nerve drives the cholinergic anti-inflammatory pathway — associated with lower pro-inflammatory cytokines (e.g. TNF-α, IL-6) and higher anti-inflammatory signalling (e.g. IL-10).
Chronic stress keeps the body in a low-grade inflammatory state — pro-inflammatory cytokines stay elevated, which is linked to fatigue, poor sleep and a body that struggles to recover.
Stimulating the vagus nerve activates the cholinergic anti-inflammatory pathway — the body's own brake on inflammation. Over consistent sessions the aim is a calmer inflammatory baseline, with more energy available for recovery rather than defence.
Lull helps rebalance the body's stress and recovery systems
By shifting activity toward the parasympathetic branch, taVNS supports heart-rate variability, recovery and overall autonomic balance.
Your autonomic nervous system has two branches: sympathetic ("fight or flight") and parasympathetic ("rest and digest"). Modern life keeps many people stuck on the sympathetic side — wired, tense and slow to recover.
taVNS nudges the balance back toward the parasympathetic side — the state in which heart-rate variability, digestion, sleep and recovery are regulated. The goal isn't to sedate you; it's to help the system return to balance on its own.
The mechanisms of Lull neuromodulation
Lull sends gentle electrical impulses to the vagus nerve at the ear — a mechanism that independent taVNS research has associated with:
61% increase in vagus-nerve activity & 18% improved heart-rate variability
The parasympathetic nervous system is the body's internal relaxation & rest mechanism, and HRV is an indicator of vagus-nerve activity. Improving these parameters of HRV indicates targeted stimulation of the vagus nerve and activation of the body's self-repair mechanisms. In a clinical trial, a one-hour taVNS session favourably altered all three parameters of Heart Rate Variability (HRV) compared to a placebo: High-Frequency HRV significantly increased (p=0.001), Low-Frequency HRV significantly decreased (p=0.001), and the ratio of LF to HF significantly decreased (p=0.002).
Source: Geng et al., 2022, PLOS ONE — taVNS increases heart-rate variability in healthy adults. Independent taVNS research, not a study of the Lull device.
35% reduction in anxious thoughts
Studies have shown that pre-existing symptoms such as anxious thoughts can further heighten the risk of symptoms associated with chronic inflammation. Research on taVNS neuromodulation has shown that it activates the vagus nerve, leading to a reduction in anxious thoughts and stress responses — increasing vagal tone and inhibiting cytokine production in the inflammatory process. The figure illustrates changes in anxiety across three timepoints: pre-intervention (D0), post-intervention (D10) (D0 vs D10, p<0.001), and 1-month follow-up (D0 vs Follow-up, p<0.001).
Source: Borges et al., 2019, Behavioural Brain Research — taVNS and emotional regulation under stress. Independent taVNS research, not a study of the Lull device.
48% reduced fatigue & increased energy
taVNS neuromodulation has demonstrated a beneficial effect on fatigue by modulating the autonomic nervous system, leading to enhanced energy and reduced exhaustion. In the study, patients reported sustained improvements even one week after discontinuing therapy, indicating prolonged relief. Fatigue was assessed using the Pichot fatigue scale during therapy (D0: day 0, D5: day 5, D10: day 10). The results showed a substantial reduction in fatigue — approximately 48% improvement (D0 vs D10, p<0.0001).
Source: Ertürk et al., 2026 — post-exercise taVNS reduced perceived fatigue (randomised controlled trial). Independent taVNS research, not a study of the Lull device.
31% improvement in sleep scores
In individuals with sleep-onset difficulties, the sympathetic branch of the autonomic nervous system may show heightened activity compared to the parasympathetic branch, resulting in increased agitation. The study demonstrated that taVNS neuromodulation enhances parasympathetic activity, which in turn mitigates agitation and improves sleep scores. The figure shows changes in sleep (PSQI Sleep Disturbance Score) across three timepoints: pre-intervention, 2 weeks and 4 weeks (p<0.05).
Source: Zhang et al., 2024, JAMA Network Open — taVNS for chronic insomnia (randomised controlled trial). Independent taVNS research, not a study of the Lull device.
Lull research at a glance
Not just mapping the nervous system. We're learning to talk to it with scientific precision.
Neural pathways and potential mechanisms involved in neuromodulation using low-level tragus stimulation.
At the heart of Lull's approach is one central challenge — how to send gentle bioelectrical signals that reach and engage precisely the right brain centres, without disturbing the rest of the system.
Stimulating the vagus nerve at the ear (the tragus) sends afferent signals up into brainstem and regulatory centres, which in turn shape efferent output back to the body. The proposed mechanisms — reduced sympathetic (anti-adrenergic) drive, neural remodeling and lower inflammation — are still being studied, and describe taVNS as a method rather than proven effects of this specific device.
References
- Zheng, Z. S., Simonian, N., Wang, J., & Rosario, E. R. (2024). Transcutaneous vagus nerve stimulation improves Long COVID symptoms in a female cohort: A pilot study. Frontiers in Neurology, 15, 1393371. https://doi.org/10.3389/fneur.2024.1393371
- Verbanck, P., Clarinval, A. M., Burton, F., Corazza, F., Nagant, C., & Cheron, G. (2021). Transcutaneous auricular vagus nerve stimulation (tVNS) can reverse the manifestations of the Long-COVID syndrome: A pilot study. Frontiers in Neurology and Neuroscience Research, 2, Article 100011. https://quintet.no/…/100011.pdf
- Dolcini, G., Favretti, M., Franculli, D., Buoncuore, G., Pellegrino, G., Di Carlo, M., Sarzi-Puttini, P., Conti, F., Iannuccielli, C., & Di Franco, M. (2025). Vagal nerve stimulation and fibromyalgia: An additional therapeutic option. Clinical and Experimental Rheumatology, 43(6), 1095–1104. https://doi.org/10.55563/clinexprheumatol/johqvo
- Mbikyo, M. B., Wang, A., Ma, Q., Miao, L., Cui, N., Yang, Y., Fu, H., Sun, Y., & Li, Z. (2024). Low-level tragus stimulation attenuates blood pressure in young individuals with hypertension: Results from a small-scale single-blind controlled randomized clinical trial. Journal of the American Heart Association, 13(19), e032269. https://doi.org/10.1161/JAHA.123.032269
- Thakkar, V. J., Richardson, Z. A., Dang, A., & Centanni, T. M. (2023). The effect of non-invasive vagus nerve stimulation on memory recall in reading: A pilot study. Behavioural Brain Research, 438, 114164. https://doi.org/10.1016/j.bbr.2022.114164
- Dasari, T. W., Akhtar, K. H., Amil, F., Zhao, Y. D., Sohinki, D., & Po, S. (2023). Effects of low-level tragus stimulation on inflammation in acute decompensated heart failure. Journal of Cardiac Failure, 29(4), 660–661. https://doi.org/10.1016/j.cardfail.2022.10.278
- Jackowska, M., Koenig, J., Vasendova, V., & Jandackova, V. K. (2022). A two-week course of transcutaneous vagal nerve stimulation improves global sleep: Findings from a randomised trial in community-dwelling adults. Autonomic Neuroscience: Basic & Clinical, 240, 102972. https://doi.org/10.1016/j.autneu.2022.102972
- Stavrakis, S., Chakraborty, P., Farhat, K., Whyte, S., Morris, L., Abideen Asad, Z. U., Karfonta, B., Anjum, J., Matlock, H. G., Cai, X., & Yu, X. (2024). Noninvasive vagus nerve stimulation in postural tachycardia syndrome: A randomized clinical trial. JACC: Clinical Electrophysiology, 10(2), 346–355. https://doi.org/10.1016/j.jacep.2023.10.015
The studies above investigate transcutaneous auricular vagus nerve stimulation (taVNS) as a method — not the Lull device. They are cited to describe the underlying mechanism, and do not represent clinical results for this specific product.